Oncotarget

Research Papers:

Characterization of the CD49f+/CD44+/CD24 single-cell derived stem cell population in basal-like DCIS cells

Nadire Duru, Ramkishore Gernapudi, Pang-Kuo Lo, Yuan Yao, Benjamin Wolfson, Yongshu Zhang and Qun Zhou _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:47511-47525. https://doi.org/10.18632/oncotarget.10203

Metrics: PDF 1332 views  |   HTML 2358 views  |   ?  


Abstract

Nadire Duru1, Ramkishore Gernapudi1, Pang-Kuo Lo1, Yuan Yao1, Benjamin Wolfson1, Yongshu Zhang1, Qun Zhou1

1Department of Biochemistry and Molecular Biology, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Correspondence to:

Qun Zhou, email: [email protected]

Keywords: tumor heterogeneity, single cell cloning, cancer stem cells, DCIS, non-coding RNAs

Received: March 29, 2016     Accepted: June 09, 2016     Published: June 21, 2016

ABSTRACT

The molecular mechanisms responsible for the Ductal Carcinoma in Situ (DCIS)-Invasive Ductal Carcinoma (IDC) transition have yet to be elucidated. Due to the lack of molecularly targeted therapies, basal-like DCIS has a high risk of recurrence and progression to invasive and metastatic cancers. In this study, by applying a novel single-cell clonogenic approach with the CD49f+/CD44+/CD24 surface markers, we characterized the aggressive clones that have enhanced self-renewal, migratory and invasive capacities derived from a human DCIS model cell line MCF10DCIS. The aggressive clones had elevated ALDH1 activity, lower global DNA methylation and increased expression of stem cell related genes, especially concurrent activation of SOX2/OCT4. In addition, we showed that the aggressive clones have increased expression of lincRNA-RoR and miR-10b compared to non-aggressive clones, which enhance their self-renewal and invasive abilities. Finally, we confirmed our in vitro results in vivo, demonstrating that aggressive clones were capable of forming tumors in nude mice, whereas non-aggressive clones were not. Our data suggest that lincRNA-RoR and miR10b could be used to distinguish aggressive clones from non-aggressive clones within the heterogeneous CD49f+/CD44+/CD24 DCIS population. Our findings also provide the foundation to develop new chemoprevention agents for DCIS-IDC transition.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10203